Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-1761981 in Solid Tumors
NCT07525141Phase 1Recruiting
- Sponsor
- Johnson & Johnson
- Start
- May 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JNJ-1761981 in solid tumor (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Number of Participants with Adverse Events (AE) by Severity, Number of Participants with Dose-Limiting Toxicities (DLTs) at 28 days and 3 more. Started May 2026; status: recruiting.
02
Drugs
JNJ-1761981
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07525141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525141.